Rankings / Hormones & Endocrine

PT-141 (Bremelanotide / Vyleesi)

Hormones & Endocrine · Melanocortin receptor agonist

Tier C+

Reviewed by Read Off Label · Last reviewed · How we grade

mc4rpeptideresearch-onlyprescription
5.5 / 10
Tier C+
Ev 6 Bn 5 Sf 5

Bottom line

Read Off Label grades PT-141 (Bremelanotide / Vyleesi) as C+ (5.5/10) based on moderate evidence, moderate benefit magnitude, and a med-risk safety profile.

AMAG Pharma's approval came with significant Rx uptake challenges — nausea is common.

Studied, labeled, or reported-use context: 1. — Rx (Vyleesi, on-demand); research peptide gray market for off-label male use; not individualized guidance.

What the evidence says

AMAG Pharma's approval came with significant Rx uptake challenges — nausea is common. Off-label use in men for 'libido enhancement' popular in biohacker circles despite not being formally studied. Shares MC1R activity with Melanotan II — some tanning/darkening with repeated use.

Mechanism

Cyclic heptapeptide; non-selective melanocortin receptor agonist (MC3R, MC4R most relevant for sexual function); acts centrally to increase sexual desire; FDA-approved for premenopausal HSDD in women

Studied, labeled, or reported dose & route

1.75 mg subQ 45 min before sexual activity; max 8 doses/month

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about PT-141 (Bremelanotide / Vyleesi)'s effects?
Read Off Label rates the evidence for PT-141 (Bremelanotide / Vyleesi) as Moderate and the benefit magnitude as moderate, producing an overall grade of C+ (5.5/10). AMAG Pharma's approval came with significant Rx uptake challenges — nausea is common.
What safety findings are reported for PT-141 (Bremelanotide / Vyleesi)?
PT-141 (Bremelanotide / Vyleesi) has a med risk profile in the database. Med (nausea — 40% in trials, often dose-limiting; flushing; headache; transient BP elevation; skin darkening with repeated use) Legal status: Rx (Vyleesi, on-demand); research peptide gray market for off-label male use.
What doses or routes are reported for PT-141 (Bremelanotide / Vyleesi)?
1.75 mg subQ 45 min before sexual activity; max 8 doses/month This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does PT-141 (Bremelanotide / Vyleesi) work?
Cyclic heptapeptide; non-selective melanocortin receptor agonist (MC3R, MC4R most relevant for sexual function); acts centrally to increase sexual desire; FDA-approved for premenopausal HSDD in women

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.